Table 4.
Risk of herpes zoster events among participants in the nested case-control study.
| Case(N = 554) | Control (N = 4944) | Crude odds ratio (95% CI) | Adjusted odds ratio (95% CI) | ||
|---|---|---|---|---|---|
| Events after first dose and before second dose | |||||
| Not vaccinated | 511 | 4490 | |||
| CoronaVac (0–13 days) | 9 | 30 | 2.78 (1.30–5.91) | 3.44 (1.56–7.56) | |
| BNT162b2 (0–13 days) | 11 | 39 | 2.27 (1.14–4.51) | 2.60 (1.29–5.25) | |
| Not vaccinated | 511 | 4417 | |||
| CoronaVac (14–27 days) | 4 | 34 | 1.06 (0.37–3.00) | 1.20 (0.41–3.47) | |
| BNT162b2 (14–27 days) | 7 | 16 | 3.46 (1.42–8.46) | 3.93 (1.50–10.26) | |
| Events after second dose | |||||
| Not vaccinated | 511 | 4416 | |||
| CoronaVac (0–13 days) | 3 | 32 | 0.78 (0.24–2.58) | 0.88 (0.26–2.96) | |
| BNT162b2 (0–13 days) | 7 | 36 | 1.63 (0.70–3.79) | 2.01 (0.84–4.77) | |
| Not vaccinated | 511 | 4347 | |||
| CoronaVac (14–27 days) | 0 | 29 | NA | NA | |
| BNT162b2 (14–27 days) | 2 | 21 | 0.71 (0.16–3.04) | 0.70 (0.16–3.14) | |
Cases and controls were matched according to age, sex, admission date and Charlson Comorbidity index. Odds ratios for herpes zoster events were estimated by conditional logistic regression adjusted for smoking status, medical history (diabetes, hypertension, asthma, malignancy, respiratory infections, viral infections, rheumatoid arthritis and other inflammatory polyarthropathies, stroke or systemic embolism, Guillain-Barré Syndrome, migraine), and medication use in the past 90 days (antiviral drugs, glucocorticoids, antibacterial drugs, immune-suppressants, lipid lowering agents). CI =confidence interval. NA = not applicable.